Oragenics (NYSE:OGEN) Coverage Initiated at StockNews.com

StockNews.com started coverage on shares of Oragenics (NYSE:OGEN) in a research report report published on Tuesday morning. The firm issued a sell rating on the stock.

Oragenics Price Performance

OGEN stock opened at $0.32 on Tuesday. Oragenics has a 52-week low of $0.28 and a 52-week high of $7.74. The company’s 50 day simple moving average is $0.38 and its 200-day simple moving average is $1.03. The firm has a market capitalization of $1.79 million, a P/E ratio of -0.05 and a beta of 0.49.

Institutional Trading of Oragenics

An institutional investor recently bought a new position in Oragenics stock. Virtu Financial LLC bought a new position in shares of Oragenics, Inc. (NYSE:OGEN) in the first quarter, according to the company in its most recent filing with the SEC. The firm bought 22,675 shares of the company’s stock, valued at approximately $33,000. Virtu Financial LLC owned approximately 0.51% of Oragenics as of its most recent SEC filing. Institutional investors and hedge funds own 18.71% of the company’s stock.

Oragenics Company Profile

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.